Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

3542 - Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial

Date

09 Sep 2017

Session

Sarcoma

Topics

Cytotoxic Therapy;  GIST

Presenters

Paolo G. Casali

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

P.G.G. Casali1, A. Le Cesne2, A. Poveda3, D. Kotasek4, P. Rutkowski5, P. Hohenberger6, E. Fumagalli7, I. Judson8, A. Italiano9, H. Gelderblom10, N. Penel11, H. Kopp12, D. Goldstein13, J. Martin Broto14, A. Gronchi15, E. Wardelmann16, S. Marreaud17, J. Zalcberg18, S. Litière19, J. Blay20

Author affiliations

  • 1 Adult Mesenchymal Tumour And Rare Cancer Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Oncología Médica, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 4 Medical Oncology, Adelaide Cancer Centre, 5037 - Adelaide/AU
  • 5 Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 6 Interdisziplinäres Tumorzentrum, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 7 Struttura Complessa Oncologia Medica Dei Tumori Mesenchimali Dell'adulto E Tumori Rari, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 8 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 9 Medicine, Institute Bergonié, 33076 - Bordeaux/FR
  • 10 Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL
  • 11 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 12 Medical Center Ii, Universitätsklinikum Tübingen Medizinische Universitätsklinik, 72076 - Tübingen/DE
  • 13 Medical Oncology, University of New South Wales Cancer Research Centre, 2052 - Sydney/AU
  • 14 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 15 Department Of Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 16 Zentralklinikum, Universitätsklinikum Münster, 48149 - Münster/DE
  • 17 Medical, EORTC, 1200 - Brussels/BE
  • 18 Faculty Of Medicine, Monash University, 3004 - Melbourne/AU
  • 19 Statistics, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 20 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3542

Background

In 2004, we started an inter-group randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk GIST patients. Interim analyses results were published in 2015 upon recommendation from an independent data review committee. We now report on the final outcome of the study.

Methods

This was a randomized, open label, multicenter phase III trial performed at 112 hospitals in 12 countries. Patients were randomized to 2 years (yrs) of imatinib, 400 mg daily, or no further therapy after surgery. The primary end-point was imatinib failure-free survival (IFFS), while relapse-free survival (RFS), relapse-free interval (RFI), overall survival (OS) and toxicity were secondary end-points. Adjusting for the interim analyses, results on IFFS will be assessed on a 4.3% significance levels; for the other endpoints 5% was used.

Results

908 patients were randomized between December 2004 and October 2008, 454 to imatinib and 454 to observation. 835 patients were eligible. With a median follow-up of 9.1 years, 5 (10)-year IFFS was 87% (75%) in the imatinib arm versus 83% (74%) in the control arm (HR = 0.87, 95.7% CI [0.65; 1.15], p = 0.31); RFS was 70% versus 63% at 5 years and 63% vs 61% at 10 years, (HR = 0.71, 95% CI [0.57; 0.89], p = 0.002); OS was 93% versus 92% at 5 years and 80% versus 78% at 10 years (HR = 0.88, 95% CI [0.65; 1.21], p = 0.43). Among 526 patients with high-risk GIST by local pathology, 10-year IFFS and RFS were 69% versus 61%, and 48% versus 43% respectively.

Conclusions

With 9.1 years of follow-up, a trend toward better long-term IFFS and RFS in Imatinib treated patients was observed in the high risk subgroup. Although not statistically significant, this trend is consistent with the results reported by the Scandinavian/German trial, showing a sustained small but significant long-term OS benefit in high risk GIST patients treated with 3 years adjuvant Imatinib. On the contrary our study discourages the use of Imatinib in patients affected by low risk (as per current standards) GIST, as long term IFFS and RFS are superimposable.

Clinical trial identification

EUDRACT 2004-001810-16, NCT00103168

Legal entity responsible for the study

EORTC HQ

Funding

Novartis

Disclosure

P.G. Casali: Research funds (institution): Amgen, Bayer, Eli Lilly, Daiichi Sankyo, Epizyme, Novartis, Pharmamar. Advisory: Bayer, Blueprint, Eisai, EliLilly, Merck SD, Merck Serono, Nektar Therapeutics, Novartis, Pfizer, Pharmamar. Honoraria: Bayer, Novartis, Pfizer, Pharmamar. A. Le Cesne: Pharmamar, Lilly, Pfizer, Novartis, Amgen Honoraria, myself, compensated. P. Rutkowski: Novartis, BMS, Roche, MSD, GSK, Amgen. P. Hohenberger: Honoraria, consultation fees and research support from Novartis. H. Gelderblom: My institution (LUMC) received study grants form Novartis. D. Goldstein: Research grants to institution, Pfizer, Amgen, Celgene, unremunerated advisory - Celgene, Shire, Pfizer, Bayer. A. Gronchi: Honoraria and compensation for advisory boards from Novartis honoraria from Pfizer compensation for advisory boards from Bayer. J. Zalcberg: Research support from Novartis and Bayer. J-Y. Blay: Research support and honoraria from Novartis, GSK, Bayer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.